Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 25;15(8):e0238021.
doi: 10.1371/journal.pone.0238021. eCollection 2020.

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Paul Jank  1 , Claire Gehlhaar  2   3 , Lederer Bianca  4 , Fontanella Caterina  5 , Schneeweiss Andreas  6 , Thomas Karn  7 , Frederik Marmé  8 , Hans-Peter Sinn  9 , Marion van Mackelenbergh  10 , Bruno Sinn  11 , Dirk-Michael Zahm  12 , Barbara Ingold-Heppner  13 , Christian Schem  14 , Elmar Stickeler  15 , Peter A Fasching  16 , Valentina Nekljudova  4 , Eliane Tabea Taube  11 , Frank Heppner  2 , Volkmar Müller  17 , Carsten Denkert  1 , Sibylle Loibl  4
Affiliations

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Paul Jank et al. PLoS One. .

Erratum in

  • Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
    Jank P, Gehlhaar C, Lederer B, Fontanella C, Schneeweiss A, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, Zahm DM, Ingold-Heppner B, Schem C, Stickeler E, Fasching PA, Nekljudova V, Taube ET, Heppner F, Müller V, Denkert C, Loibl S. Jank P, et al. PLoS One. 2021 Sep 1;16(9):e0257142. doi: 10.1371/journal.pone.0257142. eCollection 2021. PLoS One. 2021. PMID: 34469495 Free PMC article.

Abstract

Triple-negative breast cancer (TNBC) is typically treated with chemotherapeutic agents, including carboplatin (Cb), an DNA platinating agent. The O6-methylguanine-DNA-methyltransferase gene (MGMT) encodes for the protein O6-alkylguanine-DNA-alkyltransferase (MGMT protein). MGMT protein is involved in DNA repair mechanisms to remove mutagenic and cytotoxic adducts from O6-guanine in DNA. In glioblastoma multiforme, MGMT methylation status is a predictive biomarker for increased response to temozolomide therapy. It has been suggested, that MGMT protein may have relevance for cellular adaptation and could have an influence on resistance to carboplatin therapy. We investigated the influence of MGMT promoter methylation on pathologic complete response and survival of patients with TNBC treated in the neoadjuvant GeparSixto trial. In 174 of 210 available TNBC tumors a valid MGMT promoter methylation status was determined by pyrosequencing of 5 CpG islands. In 21.8%, we detected a mean MGMT promoter methylation >10%. Overall, MGMT promoter methylation was not significantly associated with pathological complete response (pCR) rate. After stratification for the two therapy arms with and without Cb no statistically significant differences in therapy response rates between the two MGMT promoter methylation groups could be observed. Our results show that different MGMT promoter methylation status is not related to different chemotherapy response rates in the TNBC setting in GeparSixto.

PubMed Disclaimer

Conflict of interest statement

I have read the journal's policy and the authors of this manuscript have the following competing interests: Dr. Schneeweiss reports grants from Celgene, grants from Roche, grants from AbbVie, grants from Molecular Partner, personal fees from Roche, personal fees from AstraZeneca, personal fees from Celgene, personal fees from Roche, personal fees from Roche, personal fees from Celgene, personal fees from Pfizer, personal fees from AstraZeneca, personal fees from Novartis, personal fees from MSD, personal fees from Tesaro, personal fees from Lilly, personal fees from Pfizer, other from Roche, outside the submitted work. Dr. v. Mackelenbergh reports travel grants and honoria from AstraZeneca, Amgen, Gebomic Health, Novartis, Lilly. Dr. Denkert reports personal fees from Novartis, personal fees from Roche, personal fees from MSD Oncology, from Daiichi Sankyo, grants from Myriad Genetics, other from Sividon Diagnostics / Myriad, outside the submitted work; In addition, Dr. Denkert has a patent EP18209672 pending, a patent EP20150702464 pending, and a patent Software (VMscope digital pathology) pending. All other authors declare no conflict of interest. We confirm that the patents do not alter our adherence to PLOS ONE policies on sharing data and materials. We would like to point out, that the patents had been added as general COI information but are not related to MGMT methylation.

Figures

Fig 1
Fig 1. CONSORT diagram for MGMT promoter methylation trial in triple-negative (TNBC) GeparSixto (G6) cohort.
Fig 2
Fig 2. MGMT promoter methylation according to therapy regime in the GeparSixto trial, neoadjuvant treatment with and without addition of carboplatin.
A. percent of patients with MGMT methylation status as binary variable (MGMTbi) B. percent of patients with MGMT methylation status as continuous variable (MGMTco).
Fig 3
Fig 3. Pathological complete response (pCR) rate according to MGMT promoter methylation status (binary), therapy regime (with or without carboplatin) and BRCA mutation status.
Therapy regime: no Cb = non-Carboplatin arm, Cb = Carboplatin arm. BRCA: wt = BRCA wildtype, mut = BRCA mutated. P values shown are calculated by Fisher‘s exact test.
Fig 4
Fig 4. Kaplan-Meier analysis for comparison of prognosis of patients with MGMT promoter un-/methylated TNBC.
DFS and OS time in months with binary MGMT promoter methylation status; p-values: log rank test.
See this image and copyright information in PMC

References

    1. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 2010;12 Suppl 2:S3. - PMC - PubMed
    1. Gao Y, Feng B, Han S, Lu L, Chen Y, Chu X, et al. MicroRNA-129 in Human Cancers: from Tumorigenesis to Clinical Treatment. Cell Physiol Biochem. 2016;39(6):2186–202. 10.1159/000447913 - DOI - PubMed
    1. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92. 10.1016/j.cell.2007.01.029 - DOI - PMC - PubMed
    1. Simo-Riudalbas L, Esteller M. Cancer genomics identifies disrupted epigenetic genes. Hum Genet. 2014;133(6):713–25. 10.1007/s00439-013-1373-5 - DOI - PubMed
    1. Spitzwieser M, Holzweber E, Pfeiler G, Hacker S, Cichna-Markl M. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer. Breast Cancer Res. 2015;17:125 10.1186/s13058-015-0637-5 - DOI - PMC - PubMed

Publication types

MeSH terms